Can Teenagers Take GLP-1 Medications?

Introduction

Yes, Wegovy® (semaglutide 2.4 mg) is FDA-approved for adolescents aged 12 and older with obesity, and Saxenda® has been approved for teens since 2020. The approval is based on the STEP TEENS trial (Weghuber et al. 2022 NEJM), which enrolled 201 adolescents aged 12 to 17 and reported a 16.1% reduction in BMI at 68 weeks.

That’s a real, evidence-based pediatric indication. It’s not off-label. It’s not experimental. It is, however, narrowly applied. Most insurers add prior authorization, BMI thresholds, and program requirements. Many pediatric obesity programs prefer trying intensive behavioral interventions first.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Does the FDA Actually Approve for Teens?

Wegovy was approved for adolescents 12 and older in December 2022 for chronic weight management, with a BMI in the 95th percentile or higher for age and sex. Saxenda was approved in December 2020 for the same age group.

Quick Answer: Wegovy is FDA-approved for ages 12+ with obesity (BMI at or above 95th percentile)

Ozempic® and Mounjaro® carry adult-only indications for type 2 diabetes. Compounded versions used in adolescents fall into a regulatory gray zone, and most reputable telehealth platforms decline to prescribe to minors.

The FDA approval was based on a randomized, double-blind, placebo-controlled trial. Adolescents on semaglutide 2.4 mg weekly lost 16.1% of BMI compared to a 0.6% gain on placebo. About 73% of teens on semaglutide achieved at least 5% weight loss.

What Did STEP TEENS Find About Safety?

The most common side effects were nausea (42%), vomiting (36%), and diarrhea (22%), similar to adult profiles. About 11% of teens on semaglutide discontinued for adverse events versus 1% on placebo.

There were no signals for thyroid C-cell tumors, severe hypoglycemia, or psychiatric events. One concern that gets raised, increased suicidal ideation, was not seen in STEP TEENS or in subsequent observational data.

Growth and development weren’t disrupted in the 68-week trial. Bone density was monitored. Pubertal progression continued normally. The follow-up duration is still limited, which the FDA labeling acknowledges.

How Do Pediatricians Decide Whether to Prescribe?

The American Academy of Pediatrics published updated clinical practice guidelines in January 2023 endorsing pharmacotherapy for adolescents 12 and older with obesity, alongside intensive health behavior and lifestyle treatment.

This was a significant shift. Prior guidelines focused on lifestyle change as the primary treatment, with pharmacotherapy reserved for failure cases. The 2023 update treats obesity as a chronic disease that warrants the same multi-modal treatment as adult disease.

Pediatricians typically require a thorough workup, including thyroid panel, glucose testing, lipid panel, blood pressure, mental health screening, and family history review. A multidisciplinary program with dietitian and behavioral support is usually paired with medication.

What About Tirzepatide for Teens?

Tirzepatide is not yet FDA-approved for adolescents. The SURMOUNT-ADOLESCENTS trial began enrolling in 2023 and is expected to report initial results in 2026 or 2027. Adult data from SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9% weight loss at 72 weeks.

Some clinicians prescribe tirzepatide off-label for adolescents under specific circumstances, particularly when semaglutide hasn’t worked or hasn’t been tolerated. This is uncommon and usually limited to pediatric obesity specialty programs.

Insurance won’t reimburse off-label tirzepatide for teens, and most pediatric guidelines don’t endorse it pending trial data.

What Are the Long-term Concerns Parents Ask About?

Three concerns come up repeatedly. First, whether weight loss medications during adolescence affect growth. Trial data so far shows normal growth velocity, but no trial has followed adolescents for more than 2 to 3 years.

Second, whether body image and disordered eating get worse. The opposite signal showed up in STEP TEENS. Adolescents on semaglutide reported reduced food noise and improved psychological measures. The team monitored for eating disorder symptoms and didn’t find an increase.

Third, what happens when the medication stops. STEP 1 (adult trial, Wilding et al. 2021 NEJM) showed about two-thirds of weight regained within a year of stopping semaglutide. Adolescents likely follow a similar pattern, which is why pediatric programs frame this as long-term chronic disease management, not a short course of treatment.

Key Takeaway: Saxenda (liraglutide) has been approved for teens since 2020

Who Is the Right Candidate Among Teens?

The AAP guideline candidate is an adolescent 12 or older with a BMI at or above the 95th percentile, paired with intensive behavioral intervention. Comorbidities like prediabetes, hypertension, sleep apnea, or fatty liver strengthen the case.

Adolescents with severe obesity (BMI at or above 120% of the 95th percentile) tend to respond well and are more likely to qualify for bariatric surgery if pharmacotherapy plus lifestyle change doesn’t work.

The wrong candidate looks like a normal-weight teen pushing for medication for cosmetic reasons, a teen with active eating disorder symptoms, or a family that hasn’t engaged with the behavioral support side.

What Does GLP-1 Cost for Teens?

Brand Wegovy lists around $1,349 per month in early 2026. Coverage varies wildly. Some commercial plans cover Wegovy for pediatric patients with prior authorization. Many state Medicaid programs cover it. Some don’t.

Novo Nordisk’s NovoCare program offers Wegovy at $499 for cash-pay, regardless of age. The Saxenda monthly cost runs around $1,400 retail, with similar manufacturer support options.

Compounded semaglutide is generally not appropriate for minors. Most telehealth platforms set 18 as the minimum age. Platforms like TrimRx offer adult care through a free assessment quiz and personalized treatment plan but do not treat minors.

How Does Bariatric Surgery Fit In?

Bariatric surgery has been performed safely in adolescents since the early 2000s. The Teen-LABS study followed 242 adolescents who had Roux-en-Y gastric bypass or sleeve gastrectomy and reported sustained weight loss and improvement in comorbidities at 5 years.

For severe adolescent obesity, surgery and GLP-1 medications are complementary rather than competing. Many pediatric obesity programs offer both tracks. Surgery candidates typically have BMI at or above 35 with major comorbidities or BMI at or above 40.

The 2023 AAP guidelines explicitly include bariatric surgery as an option for adolescents 13 and older with severe obesity, a shift from earlier age cutoffs.

Bottom line: Tirzepatide is not yet FDA-approved for adolescents (SURMOUNT-ADOLESCENTS pending)

FAQ

What’s the Youngest Age FDA-approved for GLP-1?

Twelve, with Wegovy and Saxenda. There’s no FDA-approved GLP-1 for children under 12 for any weight indication.

Do Teens Get the Same Side Effects as Adults?

Yes, with nausea, vomiting, and diarrhea as the leading complaints. Rates in STEP TEENS were similar to adult trials. Slow dose titration helps.

Will My Teen Need to Stay on It Forever?

Probably long-term, though that picture is still evolving. Obesity is a chronic relapsing condition, and stopping medication leads to significant regain in adults. Pediatric obesity specialists generally frame treatment as multi-year minimum.

Does Insurance Cover GLP-1 for Adolescents?

Commercial coverage is improving but inconsistent. Prior authorization typically requires documented BMI at or above the 95th percentile, prior behavioral intervention, and a comorbidity. Medicaid coverage varies by state.

Are There Safer Alternatives for Teens with Mild Obesity?

For BMI between the 85th and 95th percentile (overweight, not obese), intensive lifestyle treatment without medication remains first-line. The AAP guideline reserves pharmacotherapy for obesity, not overweight.

What About Ozempic for Diabetic Teens?

Ozempic is FDA-approved for type 2 diabetes in adults only. The pediatric equivalent for type 2 diabetes in teens is metformin first, then insulin or, off-label, GLP-1s in specialty settings. The pediatric trials for semaglutide in T2D are ongoing.

Can a 17-year-old Get Compounded Semaglutide?

Most telehealth platforms require age 18 or older. A few offer parental-consent pathways for older minors, though this is uncommon. The brand Wegovy at age 12+ is the more clinically conservative route.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.